Multitargeted small molecule tyrosine kinase inhibitors of dual ALK and c-MET inhibition have been studied and FDA approved in non-small cell lung cancer and c-MET inhibition may be a potential therapeutic target in human lymphomas. This evidence concerns the gene MET and lymphoma.